BMS’ Opdivo plus Yervoy misses the mark in high-risk melanoma
Bristol Myers Squibb has revealed some underwhelming results for its immunotherapy combination treatment Opdivo plus Yervoy in resected high-risk melanoma patients.
In the phase III CheckMate-915 study, PD-1 inhibitor Opdivo (nivolumab) plus CTLA-4 targeting Yervoy (ipilimumab) did not result in a statistically significant improvement in recurrence-free survival in the all-comer population, comprised of patients who have had a complete surgical removal of stage IIIb/c/d or stage IV melanoma.
Back in November 2019, BMS announced that a statistically significant benefit was not reached for the co-primary endpoint of recurrence-free survival in patients whose tumours expressed PD-L1 <1%.
Read more: http://www.pharmatimes.com/news/bms_opdivo_plus_yervoy_misses_the_mark_in_high-risk_melanoma_1352486
In the phase III CheckMate-915 study, PD-1 inhibitor Opdivo (nivolumab) plus CTLA-4 targeting Yervoy (ipilimumab) did not result in a statistically significant improvement in recurrence-free survival in the all-comer population, comprised of patients who have had a complete surgical removal of stage IIIb/c/d or stage IV melanoma.
Back in November 2019, BMS announced that a statistically significant benefit was not reached for the co-primary endpoint of recurrence-free survival in patients whose tumours expressed PD-L1 <1%.
Read more: http://www.pharmatimes.com/news/bms_opdivo_plus_yervoy_misses_the_mark_in_high-risk_melanoma_1352486
